Patents by Inventor Rolf W. Pfirrmann

Rolf W. Pfirrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130189199
    Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 25, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Publication number: 20130089606
    Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.
    Type: Application
    Filed: June 1, 2011
    Publication date: April 11, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Patent number: 8394397
    Abstract: A method of treatment for preventing or inhibiting growth of cancer cells utilizes an antineoplastic composition including an antineoplastic-effective amount of a methylol transfer agent (MTA) in combination with biodegradable adhesive capable of adhering to tissue of a living subject.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: March 12, 2013
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: Ruediger Stendel, Rolf W. Pfirrmann
  • Patent number: 8304390
    Abstract: A method of treatment for preventing or reducing tumor growth in liver of a patient includes administering to the patient an effective about of taurolidine, taurultam or a mixture thereof, so as to prevent or reduce the tumor growth in the patient.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: November 6, 2012
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Patent number: 8236794
    Abstract: A method of treating mesothelioma in a mammal, whereby a methylol-containing compound is administered to the mammal intrapleurally.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: August 7, 2012
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Patent number: 8202860
    Abstract: Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 19, 2012
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: Ruediger Stendel, Rolf W. Pfirrmann
  • Patent number: 8030301
    Abstract: A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least one amino acid in combination with at least one physiologically acceptable electrolyte. Alternatively, another solution may be administered to the mammal containing a tumor-inhibiting methylol-containing compound, while concurrently administering to the mammal a further solution including the first combination with the plurality of physiologically acceptable electrolytes or the second combination with at least one said amino acid in combination with at least one physiologically acceptable electrolyte.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: October 4, 2011
    Assignee: Ed. Geistlich Soehne AG Fuer Chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20110172213
    Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 14, 2011
    Applicant: Ed. Geistlich Soehne AG fuer chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7928102
    Abstract: A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: April 19, 2011
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: Paul H. Redmond, Rolf W. Pfirrmann
  • Patent number: 7914817
    Abstract: Patients suffering from inflammatory bowel disease such as Crohn's disease or ulcerative colitis are treated either orally or intravenously with methylol transfer agents, such as taurolidine and/or taurultam. These agents can be used in combination with other drugs thereby allowing the use of smaller amounts of the other drugs and limiting unwanted side effects.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: March 29, 2011
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7910580
    Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: March 22, 2011
    Assignee: Ed. Geistlich Soehne AG Fuer Chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7892530
    Abstract: Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: February 22, 2011
    Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Publication number: 20100048542
    Abstract: Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.
    Type: Application
    Filed: October 29, 2009
    Publication date: February 25, 2010
    Applicant: ED. GEISTLICH SOHNE AG FUR CHEMISCHE INDUSTRIE
    Inventors: Ruediger STENDEL, Rolf W. PFIRRMANN
  • Publication number: 20100040667
    Abstract: A method of treatment for treating, at least partially preventing, inhibiting or reducing growth of a bone tumor in a subject, including at least partially removing a bone tumor from a subject and contacting an area of bone adjacent to where the tumor was at least partially removed with a gel containing a tumor growth-inhibiting methylol transfer agent.
    Type: Application
    Filed: September 6, 2007
    Publication date: February 18, 2010
    Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIE
    Inventor: Rolf W. Pfirrmann
  • Patent number: 7638511
    Abstract: Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: December 29, 2009
    Assignee: ED. Geistlich Sohne AG fur Chemische Industrie
    Inventors: Ruediger Stendel, Rolf W. Pfirrmann
  • Publication number: 20090156584
    Abstract: A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof.
    Type: Application
    Filed: January 4, 2007
    Publication date: June 18, 2009
    Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIE
    Inventors: Paul H. Redmond, Rolf W. Pfirrmann
  • Publication number: 20080171738
    Abstract: A method of treating a patient with breast cancer includes administering to the patient a breast cancer cell proliferation-inhibiting amount of a methylol-containing compound such as taurolidine, taurultam or a mixture thereof.
    Type: Application
    Filed: January 2, 2008
    Publication date: July 17, 2008
    Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIE
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7345039
    Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: March 18, 2008
    Assignee: Ed. Geistlich Soehne AG fuer chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7151099
    Abstract: Taurolidine and/or taurultam is administered during and after surgical removal of a cancerous tumor to treat abdominal cancer.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: December 19, 2006
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 7132413
    Abstract: Compositions and methods are provided for preventing formation of thrombosis on a liquid-contacting surface of a liquid delivery system, such as a port, catheter or port-catheter system. The liquid delivery system is connected to a patient for delivery of a liquid to the patient. The method involves contacting the surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, the thrombosis-preventing liquid further containing an anticoagulant agent. In an alternative embodiment, the liquid-contacting surface of the delivery system is contacted with a solution containing an anticoagulant agent, and thereafter contacted with a solution containing taurolidine, taurultam or a mixture thereof.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: November 7, 2006
    Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
    Inventor: Rolf W. Pfirrmann